Trent Crow, founder and president (left), and Paul Paras, founder and vice president, and the rest of the Real Simple Energy team have moved over to Arcardia with the acquisition. Photo courtesy of Real Simple Energy

February's massive winter weather disaster underscored the fragile availability and volatile cost of electricity in the Houston area and throughout Texas. Just a month after the calamity, a Washington, D.C.-based company has scooped up Houston-based Real Simple Energy to help put power back in the hands of electricity consumers in Texas.

Arcadia, a tech company that connects U.S. homeowners and renters to renewable energy, said March 17 that it had purchased Real Simple Energy. Terms of the deal for the three-year-old startup weren't disclosed.

Real Simple Energy's automated platform matches power usage with the lowest rates in the Texas marketplace to reduce electric bills. The company manages all facets of a customer's monthly power bills.

Trent Crow, co-founder and CEO of Real Simply Energy, says all eight of the company's employees have moved over to Arcadia and more workers will be hired soon. The company has maintained a mix of office and remote workers. Arcadia will look for Houston office space later this year, Crow says.

"Expansion plans include doing more of what we're doing now and offering more features for customers," says Crow, who now is Arcadia's general manager of energy services in Texas.

Aside from Crow, co-founders of Real Simple Energy are Paul Paras and Matt Herpich.

Real Simple Energy says its customers save an average of 36 percent, or $548 a year, on electricity. That figure is based on the power bill for a 2,300-square-foot home. The startup says its fixed-rate and fixed-bill plans aren't subject to the types of spikes in power prices that many Texans experienced during February's winter weather disaster.

"Recent events in the Texas market prove that customers shouldn't be exposed to wholesale or variable rates, and want an energy advocate to protect them," Kiran Bhatraju, founder and CEO of Arcadia, says in a release. "Both Arcadia and Real Simple Energy recognize the challenges Texas homeowners and renters have historically faced in the energy-buying process, and we remain committed to removing these confusing barriers. We'll always be on the customer's side, focusing on the best rate and protecting our customers from bad actors."

Crow says the struggle to bring down energy costs at his home prompted him to start the company. He spent several years as a wholesale power trader at JPMorgan Chase.

"The deregulated energy industry, especially in Texas, has underserved customers and, as a result, most customers overpay for electricity and receive poor customer service. Using technology, we are helping customers realize the promise of deregulation and always get the best fixed rates available," Crow says in a release.

This deal represents the first acquisition for Arcadia, founded in 2014. In partnership with 125 utilities in 50 states, Arcadia oversees 4.5 terawatt hours (4.5 trillion kilowatt hours) of residential demand for energy. It's the biggest manager of residential solar in the U.S.

Arcadia has raised $70.5 million in funding, according to Crunchbase.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”